Literature DB >> 11352953

Hürthle cell carcinoma: a critical histopathologic appraisal.

A Stojadinovic1, R A Ghossein, A Hoos, M J Urist, R H Spiro, J P Shah, M F Brennan, A R Shaha, B Singh.   

Abstract

PURPOSE: Controversy exists over the ability of morphology to predict the biologic behavior of Hürthle cell carcinoma. The aim of this study was to conduct a critical histopathologic review of Hürthle cell carcinoma and to correlate morphologic parameters with clinical outcome. PATIENTS AND METHODS: Patients with histologically confirmed Hürthle cell carcinoma treated between 1940 and 2000 form the basis of this study. Adenomas were excluded. Tumors of unknown malignant behavior ([UMB] n = 17) had solid growth pattern, incomplete capsular invasion (Ci), or both but no vascular invasion (Vi). Minimally invasive carcinomas ([MIC] n = 23) had one focus of intra- or extracapsular Vi, one focus of complete Ci, or both. Widely invasive carcinomas ([WIC] n = 33) demonstrated more than one focus of Vi, more than one focus of Ci, or both. The primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Rates of recurrence/death were estimated by Kaplan-Meier method. The univariate influence of prognostic factors on end points was analyzed by log-rank test, and multivariate analysis was performed by Cox regression.
RESULTS: Median follow-up was 8 years. No patients with UMB or MIC relapsed or died of disease. Of WIC, 73% relapsed and 55% died of disease. Age, size, and extent of resection did not influence outcome. Adverse predictors of RFS and DSS among WIC were extrathyroidal extension, nodal metastasis, positive margin, and solid growth pattern (P <.05). Both Ci and Vi were associated with worse DSS (P <.05). On multivariate analysis, extrathyroidal extension and nodal metastases were independent predictors of outcome (P <.05).
CONCLUSION: Patients with Hürthle cell carcinoma have a prognosis that is predicted by well-defined histomorphologic characteristics. Unlike differentiated thyroid cancer, nodal metastases predict a worse outcome in widely invasive Hürthle cell carcinoma, as does extrathyroidal extension.

Entities:  

Mesh:

Year:  2001        PMID: 11352953     DOI: 10.1200/JCO.2001.19.10.2616

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

1.  Papillary Thyroid Carcinoma Metastasis to the Lumbar Spine Masquerading as a Schmorl's Node.

Authors:  Cory P Daignault; Edwin L Palmer; James A Scott; John S Swan; Gilbert H Daniels
Journal:  Nucl Med Mol Imaging       Date:  2015-02-03

Review 2.  Encapsulated Thyroid Carcinoma of Follicular Cell Origin.

Authors:  Bin Xu; Ronald Ghossein
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 3.  Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

Authors:  B Xu; R Ghossein
Journal:  Eur J Surg Oncol       Date:  2017-05-18       Impact factor: 4.424

Review 4.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

5.  Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.

Authors:  Volkert B Wreesmann; Iain J Nixon; Michael Rivera; Nora Katabi; Frank Palmer; Ian Ganly; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ronald A Ghossein
Journal:  Thyroid       Date:  2015-03-31       Impact factor: 6.568

6.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

7.  Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules.

Authors:  Richard E Goldstein; James L Netterville; Brian Burkey; Joyce E Johnson
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

8.  Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

Authors:  Hendra Budiawan; Ali Salavati; Harshad R Kulkarni; Richard P Baum
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

9.  Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.

Authors:  Michael Rivera; Julio Ricarte-Filho; Robert Michael Tuttle; Ian Ganly; Ashok Shaha; Jeffrey Knauf; James Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

Review 10.  Update to the College of American Pathologists reporting on thyroid carcinomas.

Authors:  Ronald Ghossein
Journal:  Head Neck Pathol       Date:  2009-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.